4CPS-113. INOTUZUMAB OZOGAMIZIN FOR THE TREATMENT OF THE RELAPSE B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKAEMIA IN AN ADULT PATIENT: A CASE REPORT.

Del Río Valencia JC(2), Ortega de la Cruz C. (1), Chinchilla Alarcón T. (1), Muñoz Castillo I.(1)
(1)SERVICIO DE FARMACIA HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA
(2) SERVICIO DE FARMACIA HOSPITAL XANIT DE BENALMÁDENA (MÁLAGA)

BACKGROUND

Inotuzumab-ozogamicin is an antibody-drug conjugate (ADC) composed of a recombinant humanised IgG4 kappa CD22-directed monoclonal antibody that is covalently linked to N-acetyl-gamma-calicheamicin dimethylhydrazide. It is indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL).

AIM AND OBJECTIVES

To describe a posttransplant relapsed adult case with B-precursor ALL in which inotuzumab was successfully used as bridging therapy to perform a second haematopoietic stem cell transplantation (HSCT).

MATERIAL AND METHODS

This was an observational retrospective study of the use of inotuzumab in a 32-year-old woman diagnosed with posttransplant relapsed B-precursor ALL. The study variable was MRD response, defined as MRD level <10^-4 at the end of treatment and complete remission. The data were obtained from the digital clinical history.

RESULTS

1º HR-ALL PETHEMA-2011 <55 years protocol:
-Phase-1 induction
-Phase-2 induction
-Phase-1 consolidation

• High expression of CD-22 B lymphocytes.
• INO-VATE phase III clinical-trial.
• She was treated with 2 cycles (28-day cycles) of INOTUZUMAB.
  • Dose: Day 1- 0.8 mg/m² and day 8,15- 0.5 mg/m².
• This woman achieved MRD-negative and CR

CONCLUSION

In this case of an adult patient with high risk ALL who relapse after allogeneic transplantation of haematopoietic progenitors, the use of inotuzumab showed to be safe and effective achieving MRD and complete remission and therefore the initial goal of the study. Nevertheless, more studies are needed to demonstrate its efficacy and safety profile.

ACKNOWLEDGEMENTS

No conflict of interest

juancarlosdelrio@telefonica.net

L04 - Immunosuppressive agents